CTNNB1
CTNNB1 (Catenin beta-1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Hepatocellular carcinoma, Colorectal cancer, Ovarian cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Key downstream component of the canonical Wnt signalling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Also acts as a coactivator for other transcription factors, such as NR5A2. Promotes epithelial to mesenchymal transition/mesenchymal to epithelial transition (EMT/MET) via driving transcription of CTNNB1/TCF-target genes. Involved in the regulation of cell adhesion, as component of an E-cadherin:catenin adhesion complex. Location: Cytoplasm; Nucleus; Cytoplasm, cytoskeleton; Cell junction, adherens junction (UniProt). Locus 3p22.1 (HGNC).
- Hepatocellular carcinoma: Open Targets association 0.80 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 9 cohorts (HCC)
- Colorectal cancer: Open Targets association 0.72 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease
- Ovarian cancer: Open Targets association 0.70 with ovarian cancer (MONDO_0008170); IntOGen driver in 1 cohort (OVT)
- Lung cancer: Open Targets association 0.69 with lung cancer (MONDO_0008903)
- Endometrial cancer: Open Targets association 0.67 with endometrial cancer (MONDO_0011962); IntOGen driver in 4 cohorts (UCEC)
- Prostate cancer: Open Targets association 0.59 with prostate cancer (MONDO_0008315); IntOGen driver in 7 cohorts (PRAD, PROSTATE)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"CTNNB1" OR ABSTRACT:"CTNNB1" OR TITLE:"catenin beta 1" OR ABSTRACT:"catenin beta 1" OR TITLE:"Catenin beta-1" OR ABSTRACT:"Catenin beta-1" OR TITLE:"beta-catenin" OR ABSTRACT:"beta-catenin" OR TITLE:"armadillo" OR ABSTRACT:"armadillo" OR TITLE:"CTNNB" OR ABSTRACT:"CTNNB") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTNNB1, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ctnnb1.json. Licence CC BY-NC 4.0.